< >

HyperAcute Immunotherapy

NewLink Genetics has multiple HyperAcute immunotherapies currently under development in a variety of tumors

Phase 3 Trial in Pancreatic Cancer

Now enrolling patients with borderline resectable or locally advanced unresectable pancreatic cancer

Phase 2b/3 Trial in Lung Cancer

Now enrolling patients with progressive or relapsed non-small cell lung cancer (NSCLC)

Investor Relations

Keep up with the latest news and presentations
NewLink Genetics Supports the Fight Against Pancreatic Cancer at PurpleStride 2015 Events in Austin, Los Angeles and Des Moines
April 24, 2015

NewLink Genetics to Host Its First Quarter 2015 Earnings Results Conference Call on May 5, 2015
April 21, 2015

ANNOUNCEMENTS